Abstract

                                                                                     Biography

姜 海：中科院上海生命科学研究院生物化学与细胞生物学研究所研究员、博士生导师。2000年毕业于北京大学生命科学学院，获学士学位；2006年年毕业于美国西北大学医学院，获博士学位。2007年-2011年期间在美国麻省理工学院癌症研究中心从事科研工作，博士后。现主要从事癌症精准治疗的分子基础、癌症基因的功能与调控方面的研究。

代表性论文

1.        Li X, Zhang Y, Zheng L ,Liu M, Chen C, Jiang H.UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma.Nat Commun.2018,9:2720.

2.        Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y*, Hemann MT* , Jiang H* . A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Molecular Medicine, Advanced publication online (* Co-corresponding author)

3.        Wang N, Ding H, Liu H, Li X, Wei L, Yu J, Liu M, Ying M, Gao W, Jiang H* , Wang Y＊. A novel recurrent CHEK2 Y390C mutation identified in high risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk Oncogene, Advanced publication online DOI: ONC.2014.443 (*Corresponding author)

4.        Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. (2011) Nat Chem Biol. 7(2):92-100.

5.        Jiang H#, Reinhardt HC#, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. (2009) Genes Dev. 23(16):1895-909. (# equal contribution)